Antitumor agents 294. Novel E-ring-modified camptothecin-4β-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents. 2012

Deyong Ye, and Qian Shi, and Chung-Hang Leung, and Seung-Whan Kim, and Shin-Young Park, and Elizabeth A Gullen, and Zao Li Jiang, and Hao Zhu, and Susan L Morris-Natschke, and Yung-Chi Cheng, and Kuo-Hsiung Lee
Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7568, USA.

Two conjugates (1 and 2) of camptothecin (CPT) and 4β-anilino-4'-O-demethylepipodophyllotoxin were previously shown to exert antitumor activity through inhibition of topoisomerase I (topo I). In this current study, two novel conjugates (1E and 2E) with an open E-ring in the CPT moiety were first synthesized and evaluated for biological activity in comparison with their intact E-ring congeners. This novel class of CPT-derivatives exhibits its antitumor effect against CPT-sensitive and -resistant cells, in part, by inhibiting topo I-linked DNA (TLD) religation. An intact E-ring was not essential for the inhibition of TLD religation, although conjugates with an open E-ring were less potent than the closed ring analogs. This lower religation potency resulted in decreased formation of protein-linked DNA breaks (PLDBs), and hence, less cell growth inhibition. In addition to their impact on topo I, conjugates 1E, 2, and 2E exhibited a minor inhibitory effect on topo II-induced DNA cleavage. The novel structures of 1E and 2E may present scaffolds for further development of dual function topo I and II inhibitors with improved pharmacological profiles and physicochemical properties.

UI MeSH Term Description Entries
D011034 Podophyllotoxin A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives. Epipodophyllotoxin,CPH86,Condyline,Condylox,Podocon-25,Podofilm,Podofilox,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-Isomer,Wartec,Warticon
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D004264 DNA Topoisomerases, Type I DNA TOPOISOMERASES that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. DNA Topoisomerases, Type I enzymes reduce the topological stress in the DNA structure by relaxing the superhelical turns and knotted rings in the DNA helix. DNA Nicking-Closing Protein,DNA Relaxing Enzyme,DNA Relaxing Protein,DNA Topoisomerase,DNA Topoisomerase I,DNA Topoisomerase III,DNA Topoisomerase III alpha,DNA Topoisomerase III beta,DNA Untwisting Enzyme,DNA Untwisting Protein,TOP3 Topoisomerase,TOP3alpha,TOPO IIIalpha,Topo III,Topoisomerase III,Topoisomerase III beta,Topoisomerase IIIalpha,Topoisomerase IIIbeta,DNA Nicking-Closing Proteins,DNA Relaxing Enzymes,DNA Type 1 Topoisomerase,DNA Untwisting Enzymes,DNA Untwisting Proteins,Topoisomerase I,Type I DNA Topoisomerase,III beta, Topoisomerase,III, DNA Topoisomerase,III, Topo,III, Topoisomerase,IIIalpha, TOPO,IIIalpha, Topoisomerase,IIIbeta, Topoisomerase,Topoisomerase III, DNA,Topoisomerase, TOP3,beta, Topoisomerase III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D059004 Topoisomerase I Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASE I. DNA Topoisomerase I Inhibitor,DNA Topoisomerase III Inhibitor,DNA Topoisomerase III Inhibitors,DNA Type 1 Topoisomerase Inhibitor,DNA Type III Topoisomerase Inhibitor,DNA Type III Topoisomerase Inhibitors,Topoisomerase 1 Inhibitor,Topoisomerase 1 Inhibitors,Topoisomerase 3 Inhibitor,Topoisomerase 3 Inhibitors,Topoisomerase I Inhibitor,Topoisomerase III Inhibitor,Topoisomerase III Inhibitors,DNA Topoisomerase I Inhibitors,DNA Type 1 Topoisomerase Inhibitors,1 Inhibitor, Topoisomerase,3 Inhibitor, Topoisomerase,3 Inhibitors, Topoisomerase,I Inhibitor, Topoisomerase,III Inhibitor, Topoisomerase,III Inhibitors, Topoisomerase,Inhibitor, Topoisomerase 1,Inhibitor, Topoisomerase 3,Inhibitor, Topoisomerase I,Inhibitor, Topoisomerase III,Inhibitors, Topoisomerase 1,Inhibitors, Topoisomerase 3,Inhibitors, Topoisomerase I,Inhibitors, Topoisomerase III
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug

Related Publications

Deyong Ye, and Qian Shi, and Chung-Hang Leung, and Seung-Whan Kim, and Shin-Young Park, and Elizabeth A Gullen, and Zao Li Jiang, and Hao Zhu, and Susan L Morris-Natschke, and Yung-Chi Cheng, and Kuo-Hsiung Lee
August 1997, Bioorganic & medicinal chemistry,
Deyong Ye, and Qian Shi, and Chung-Hang Leung, and Seung-Whan Kim, and Shin-Young Park, and Elizabeth A Gullen, and Zao Li Jiang, and Hao Zhu, and Susan L Morris-Natschke, and Yung-Chi Cheng, and Kuo-Hsiung Lee
August 2022, Molecules (Basel, Switzerland),
Deyong Ye, and Qian Shi, and Chung-Hang Leung, and Seung-Whan Kim, and Shin-Young Park, and Elizabeth A Gullen, and Zao Li Jiang, and Hao Zhu, and Susan L Morris-Natschke, and Yung-Chi Cheng, and Kuo-Hsiung Lee
January 1989, Journal of natural products,
Deyong Ye, and Qian Shi, and Chung-Hang Leung, and Seung-Whan Kim, and Shin-Young Park, and Elizabeth A Gullen, and Zao Li Jiang, and Hao Zhu, and Susan L Morris-Natschke, and Yung-Chi Cheng, and Kuo-Hsiung Lee
January 2011, European journal of medicinal chemistry,
Deyong Ye, and Qian Shi, and Chung-Hang Leung, and Seung-Whan Kim, and Shin-Young Park, and Elizabeth A Gullen, and Zao Li Jiang, and Hao Zhu, and Susan L Morris-Natschke, and Yung-Chi Cheng, and Kuo-Hsiung Lee
June 2004, Bioorganic & medicinal chemistry,
Deyong Ye, and Qian Shi, and Chung-Hang Leung, and Seung-Whan Kim, and Shin-Young Park, and Elizabeth A Gullen, and Zao Li Jiang, and Hao Zhu, and Susan L Morris-Natschke, and Yung-Chi Cheng, and Kuo-Hsiung Lee
February 2013, Translational oncology,
Deyong Ye, and Qian Shi, and Chung-Hang Leung, and Seung-Whan Kim, and Shin-Young Park, and Elizabeth A Gullen, and Zao Li Jiang, and Hao Zhu, and Susan L Morris-Natschke, and Yung-Chi Cheng, and Kuo-Hsiung Lee
March 1993, Pharmaceutical research,
Deyong Ye, and Qian Shi, and Chung-Hang Leung, and Seung-Whan Kim, and Shin-Young Park, and Elizabeth A Gullen, and Zao Li Jiang, and Hao Zhu, and Susan L Morris-Natschke, and Yung-Chi Cheng, and Kuo-Hsiung Lee
November 2001, Bioorganic & medicinal chemistry,
Deyong Ye, and Qian Shi, and Chung-Hang Leung, and Seung-Whan Kim, and Shin-Young Park, and Elizabeth A Gullen, and Zao Li Jiang, and Hao Zhu, and Susan L Morris-Natschke, and Yung-Chi Cheng, and Kuo-Hsiung Lee
October 2004, Journal of medicinal chemistry,
Deyong Ye, and Qian Shi, and Chung-Hang Leung, and Seung-Whan Kim, and Shin-Young Park, and Elizabeth A Gullen, and Zao Li Jiang, and Hao Zhu, and Susan L Morris-Natschke, and Yung-Chi Cheng, and Kuo-Hsiung Lee
January 2018, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!